Abstract
The effectiveness of intranasal neostigmine (9-3-13-8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
Cite
CITATION STYLE
APA
Ricciardi, R., Rossi, B., Nicora, M., Sghirlanzoni, A., & Muratorio, A. (1951). Acute treatment of myasthenia gravis with intranasal neostigmine: Clinical and electromyographic evaluation. Journal of Neurology, Neurosurgery and Psychiatry, 54(12), 1061–1062. https://doi.org/10.1136/jnnp.54.12.1061
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free